Company Overview and News


Add LLY
to your dashboard

Headline News

United Therapeutics PAH Drug's Exclusivity Period Extended

9h zacks
United Therapeutics Corporation (UTHR - Free Report) reported that the FDA has granted six months pediatric exclusivity to its pulmonary arterial hypertension (PAH) drug, Adcirca (tadalafil). This will delay generic competition for the drug for an additional six months. (3-1)

BIIB Stock: Bet on Biogen Inc for Easy Profits Into the New Year | InvestorPlace

11h investorplace
Biotech stocks have been a political football for over a year. The negative political rhetoric started during the 2016 U.S. elections. Candidate Hillary Clinton and now President Donald Trump both have persecuted the sector for unfair pricing practices. (55-1)

Understanding Aducanumab's Potential In Alzheimer's

12h seekingalpha
Additional data from a Phase 1 trial on Aducanumab has been reported this summer, while the drug is in Phase 3 testing. (349-1)

Eli Lilly Bets Big on Insulin-Delivery Devices - WSJ

12h wsj
CAMBRIDGE, Mass.—Eli Lilly & Co., one of the biggest makers of insulin, has been planning a risky new business venture: making the high-tech devices that deliver insulin to diabetes patients. (2-0)

UPDATE 1-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

13h reuters
MÅLØV, Denmark (Reuters) - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as its established diabetes drugs come under price pressure, particularly in the United States. (2-0)

Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs - Channel NewsAsia

13h channelnewsasia
Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as its established diabetes drugs come under price pressure, particularly in the United States. (2-0)

Trump's nominee for top health job Alex Azar reaped millions from drug company

2017-11-20 nzherald.co.nz
Newly disclosed financial records show that President Donald Trump's nominee to become secretary of the Health and Human Services Department reaped big earnings during his tenure as a top pharmaceutical executive. (2-0)

Your Daily Pharma Scoop: Geron's Fate, Celldex Commences Mid-Stage Study, Novartis's Tasigna

2017-11-20 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (141-0)

Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

2017-11-20 zacks
Celldex Therapeutics, Inc. (CLDX - Free Report) announced the initiation of a phase II study on its human monoclonal antibody, CDX-3379 in patients with advanced head and neck squamous cell carcinoma ("HNSCC"). (35-0)

Industry Group Rank Restrict Eli Lilly (LLY) Rating

2017-11-17 investorplace
Eli Lilly and Company (NYSE:LLY) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top decile of sector group, Health Care, with a market value of $91.7 billion. From an investment attractiveness viewpoint, LLY is ranked in the top half of the sector with a ranking of 274 among the 782 companies in the sector; Portfolio Grader's current ranking for LLY puts it 38 among the 132 companies in this industry group, placing it in the top half and number 1,727 in the 5000 company Portfolio Grader company universe. (2-0)

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

Analyzing $CERC – TickerJunkie

2017-11-17 tickerjunkie
Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. Through this write-up, I will be covering the management team, pipeline, insider transactions and future growth. (68-0)

Novo Nordisk: Q3 2017 Results Show Strong Future Potential

2017-11-17 seekingalpha
While the company has been growing both sales and profits YOY, it is the non-North American segment delivering almost all of the growth. (2-0)

AstraZeneca’s Valuation after 3Q17 Earnings

2017-11-16 marketrealist
AstraZeneca (AZN) is a leading pharmaceutical company involved in developing and manufacturing drugs for primary care and specialty care. It operates in more than 100 countries. The company released its 3Q17 earnings on November 9, 2017. (3-0)

AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

2017-11-16 zacks
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to a new indication for its breast cancer drug, Faslodex. (63-0)